KR100616028B1 - 인자 ⅷ을 위한 발현 시스템 - Google Patents

인자 ⅷ을 위한 발현 시스템 Download PDF

Info

Publication number
KR100616028B1
KR100616028B1 KR1020017007149A KR20017007149A KR100616028B1 KR 100616028 B1 KR100616028 B1 KR 100616028B1 KR 1020017007149 A KR1020017007149 A KR 1020017007149A KR 20017007149 A KR20017007149 A KR 20017007149A KR 100616028 B1 KR100616028 B1 KR 100616028B1
Authority
KR
South Korea
Prior art keywords
leu
ser
protein
delete delete
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020017007149A
Other languages
English (en)
Korean (ko)
Other versions
KR20020013481A (ko
Inventor
명-삼 조
샴 유엔 챈
윌리암 켈시
헬레나 이
Original Assignee
바이엘 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 코포레이션 filed Critical 바이엘 코포레이션
Publication of KR20020013481A publication Critical patent/KR20020013481A/ko
Application granted granted Critical
Publication of KR100616028B1 publication Critical patent/KR100616028B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
KR1020017007149A 1998-12-10 1999-12-08 인자 ⅷ을 위한 발현 시스템 Expired - Lifetime KR100616028B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 1998-12-10
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII

Publications (2)

Publication Number Publication Date
KR20020013481A KR20020013481A (ko) 2002-02-20
KR100616028B1 true KR100616028B1 (ko) 2006-08-28

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017007149A Expired - Lifetime KR100616028B1 (ko) 1998-12-10 1999-12-08 인자 ⅷ을 위한 발현 시스템

Country Status (26)

Country Link
US (10) US6358703B1 (https=)
EP (1) EP1137797B1 (https=)
JP (1) JP4240818B2 (https=)
KR (1) KR100616028B1 (https=)
AT (1) ATE412765T1 (https=)
AU (1) AU761801B2 (https=)
BG (1) BG65431B1 (https=)
BR (1) BRPI9916069B8 (https=)
CA (1) CA2354845C (https=)
CZ (1) CZ302330B6 (https=)
DE (1) DE69939839D1 (https=)
DK (1) DK1137797T3 (https=)
ES (1) ES2315026T3 (https=)
HU (1) HU228489B1 (https=)
IL (2) IL143353A0 (https=)
NO (1) NO329544B1 (https=)
NZ (1) NZ512234A (https=)
PL (1) PL200676B1 (https=)
PT (1) PT1137797E (https=)
RO (1) RO121604B1 (https=)
RU (1) RU2249041C2 (https=)
SI (1) SI20644B (https=)
SK (1) SK286945B6 (https=)
TR (1) TR200101592T2 (https=)
UA (1) UA77383C2 (https=)
WO (1) WO2000034505A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125999A3 (en) * 2008-04-12 2010-01-14 Celltrion, Inc. Human host cell for producing recombinant proteins with high quality and quantity

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
KR100581574B1 (ko) * 2000-03-22 2006-05-22 옥타게네 게엠베하 인간 세포주 내 재조합 혈액 응고 인자의 제조
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
WO2004075923A2 (en) * 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
KR101468345B1 (ko) * 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Fviii의 부위 지향 변형
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP2253644B1 (en) 2005-12-20 2013-10-16 Bristol-Myers Squibb Company Compositions and methods for producing a composition
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
KR20110033242A (ko) * 2008-06-25 2011-03-30 바이엘 헬스케어 엘엘씨 면역원성이 감소된, 인자 ⅷ 뮤테인
CN102119172A (zh) 2008-08-21 2011-07-06 奥克塔法马股份有限公司 重组制备的人类因子viii和ix
US20110178019A1 (en) * 2008-09-03 2011-07-21 Brita Rippner New protecting compositions for recombinantly produced factor viii
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010111414A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
RU2600886C2 (ru) * 2011-05-13 2016-10-27 Октафарма Аг Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii
DK2804623T3 (da) 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
KR102415992B1 (ko) 2016-04-15 2022-07-04 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법을 제공하는 방법 및 장치
JP7618383B2 (ja) 2016-07-22 2025-01-21 ネクター セラピューティクス オキシム含有リンケージを有する第viii因子部分のコンジュゲート
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US20200245667A1 (en) * 2017-09-13 2020-08-06 Evolve Biosystems, Inc. Oligosaccharide compositions and their use during transitional phases of the mammalian gut microbiome
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
US12252528B2 (en) * 2018-10-23 2025-03-18 The Children's Hospital Of Philadelphia Compositions and methods for modulating Factor VIII function

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612213A (en) * 1993-06-10 1997-03-18 Bayer Corporation Method of selecting mammalian cell lines having improved productivity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
EP0254076B1 (en) * 1986-07-11 1991-05-08 Miles Inc. Improved recombinant protein production
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
CA2075206C (en) * 1989-12-01 2006-05-23 Herbert L. Heyneker Production of recombinant polypeptides by bovine species and transgenic methods
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6180108B1 (en) 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612213A (en) * 1993-06-10 1997-03-18 Bayer Corporation Method of selecting mammalian cell lines having improved productivity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125999A3 (en) * 2008-04-12 2010-01-14 Celltrion, Inc. Human host cell for producing recombinant proteins with high quality and quantity

Also Published As

Publication number Publication date
US20030077752A1 (en) 2003-04-24
AU2170100A (en) 2000-06-26
DK1137797T3 (da) 2009-02-23
US20160115219A1 (en) 2016-04-28
US20130143818A1 (en) 2013-06-06
BG105567A (en) 2002-03-29
JP4240818B2 (ja) 2009-03-18
EP1137797A1 (en) 2001-10-04
IL143353A (en) 2010-12-30
CA2354845A1 (en) 2000-06-15
WO2000034505A1 (en) 2000-06-15
HU228489B1 (en) 2013-03-28
HUP0200558A2 (en) 2002-06-28
SK286945B6 (sk) 2009-08-06
AU761801B2 (en) 2003-06-12
NO329544B1 (no) 2010-11-08
US20170267745A1 (en) 2017-09-21
ATE412765T1 (de) 2008-11-15
NO20012718D0 (no) 2001-06-01
US9249209B2 (en) 2016-02-02
CZ20012024A3 (cs) 2001-10-17
CZ302330B6 (cs) 2011-03-16
JP2002531137A (ja) 2002-09-24
RU2249041C2 (ru) 2005-03-27
KR20020013481A (ko) 2002-02-20
BRPI9916069B8 (pt) 2021-05-25
EP1137797B1 (en) 2008-10-29
NZ512234A (en) 2002-12-20
PL200676B1 (pl) 2009-01-30
PT1137797E (pt) 2008-12-26
US6358703B1 (en) 2002-03-19
PL349284A1 (en) 2002-07-15
US20130267468A1 (en) 2013-10-10
BG65431B1 (bg) 2008-07-31
UA77383C2 (uk) 2006-12-15
IL143353A0 (en) 2002-04-21
TR200101592T2 (tr) 2001-11-21
RO121604B1 (ro) 2007-12-28
BR9916069A (pt) 2001-09-04
US20020102730A1 (en) 2002-08-01
US20110144025A1 (en) 2011-06-16
US8207117B2 (en) 2012-06-26
SI20644B (sl) 2009-04-30
US20090036358A1 (en) 2009-02-05
US7459525B2 (en) 2008-12-02
US20020115152A1 (en) 2002-08-22
SK7922001A3 (en) 2002-01-07
SI20644A (sl) 2002-02-28
BRPI9916069B1 (pt) 2016-08-02
CA2354845C (en) 2008-08-12
ES2315026T3 (es) 2009-03-16
EP1137797A4 (en) 2005-06-22
NO20012718L (no) 2001-06-01
US9650431B2 (en) 2017-05-16
HUP0200558A3 (en) 2004-11-29
US8945869B2 (en) 2015-02-03
DE69939839D1 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
KR100616028B1 (ko) 인자 ⅷ을 위한 발현 시스템
EP0306968B1 (en) Process for producing recombinant human factor VIII:C
EP0506757B2 (en) A recombinant human factor viii derivative
US6171825B1 (en) Preparation of recombinant factor VIII in a protein free medium
JP4124493B2 (ja) 無血清培地
WO1990002175A1 (en) A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
MXPA01005667A (en) Expression system for factor viii
EP1318198B1 (en) Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
MXPA98003051A (en) Preparation of recombinant factor viii in a protei free medium

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010608

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20041118

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060222

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060803

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060818

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060821

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090813

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100809

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20110809

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20120806

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20120806

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130808

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130808

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140805

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140805

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150805

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150805

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160808

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160808

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170804

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170804

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20180730

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20180730

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20190729

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20190729

Start annual number: 14

End annual number: 14

PC1801 Expiration of term

Termination date: 20200608

Termination category: Expiration of duration